Effect of novel amino acids and dipeptides substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in alzheimer's dementia models

International Journal of Peptide Research and Therapeutics

Volumn 15, Issue 4, 2009, Pages 323-337

  Ranganatha, S R ^a   Malviya, Manish ^a   Sunil Kumar, Y C ^a   Vinaya, K ^a   Prasanna, D S ^a   Subhash, M N ^b   Rangappa, K S ^a  

^a UNIVERSITY OF MYSORE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Alzheimer's disease; M1 agonists; Morpholino arecolines; Peptide conjugates

Indexed keywords

2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 [1H INDOL 3 YL]PROPAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 HYDROXYBUTAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 HYDROXYPROPAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYLBUTAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYLPENTAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 4 METHYLPENTAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO]ETHANONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO]HEXAN 1 ONE; 2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO]PROPAN 1 ONE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 (1H IMIDAZOL 4 YL)PROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 (4 HYDROXYPHENYL)PROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 HYDROXYPROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 MERCAPTOPROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 METHYLBUTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 METHYLPENTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 3 PHENYLPROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL] 4 METHYLPENTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL]PYRROLIDINE 2 CARBOXAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL] 3 MERCAPTOPROPANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL] 3 METHYLBUTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL] 3 METHYLPENTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL] 4 METHYLPENTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL] 5 GUANIDINOPENTANAMIDE; 2 AMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 3 METHYL 1 OXOBUTAN 2 YL]PROPANAMIDE; 2,6 DIAMINO N [1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 1 OXOPROPAN 2 YL]HEXANAMIDE; [2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO] 5 OXOPENTYL]GUANIDINE; [2 AMINO 1 [2 (1,2,5,6 TETRAHYDRO 1 METHYLPYRIDIN 3 YL)MORPHOLINO][PYRROLIDIN 2 YL]METHANONE; ARECOLINE; MUSCARINIC M1 RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOM; CONTROLLED STUDY; EXPERIMENTAL MODEL; IN VIVO STUDY; LEARNING; MALE; MAZE TEST; MEMORY; NONHUMAN; PASSIVE AVOIDANCE; RAT; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

RATTUS NORVEGICUS;

EID: 70350780058     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-009-9194-z     Document Type: Article

References (35)

1. SG Anagnostaras GG Murphy SE Hamilton SL Mitchell NP Rahnama NM Nathanson AJ Silva 2003 Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice Nat Neurosci 6 51 58 10.1038/nn992 12483218 (Pubitemid 36026332)
2. JD Buxbaum M Oishi HI Chen R Pinkas-Kramarski EA Jaffe SE Gandy P Greengard 1992 Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor Proc Natl Acad Sci USA 89 10075 10078 10.1073/pnas.89.21.10075 1359534
3. JN Chandra M Malviya CT Sadashiva MN Subhash KS Rangappa 2008 Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models Neurochem Int 52 376 383 10.1016/j.neuint.2007.07.006 17719699
4. JE Christie A Shering J Ferguson AI Glen 1981 Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia Br J Psychiatry 138 46 50 10.1192/bjp.138.1.46 7023592
5. JT Coyle DL Price MR DeLong 1983 Alzheimer's disease: a disorder of cortical cholinergic innervation Science 219 1184 1190 10.1126/science.6338589 6338589
6. I Creese SH Snyder 1978 3H-spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus Eur J Pharmacol 49 201 202 10.1016/0014- 2999(78)90080-8 658137 (Pubitemid 9201002)
7. P De Sarno SA Shestopal TD King A Zmijewska L Song RS Jope 2003 Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress and mitochondrial inhibition J Biol Chem 278 11086 11093 10.1074/jbc.M212157200 12538580 (Pubitemid 36792660)
8. RM Eglen A Choppin N Watson 2001 Therapeutic opportunities from muscarinic receptor research Trends Pharmacol Sci 22 409 414 10.1016/S0165-6147(00)01737-5 11479003 (Pubitemid 32718632)
9. A Fisher 2000 Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists Jpn J Pharmacol 84 101 112 10.1254/jjp.84.101 11128032 (Pubitemid 30833879)
10. D Gabuzda J Busciglio BA Yankner 1993 Inhibition of beta-amyloid production by activation of protein kinase C J Neurochem 61 2326 2329 10.1111/j.1471-4159.1993.tb07479.x 8245986 (Pubitemid 23354098)
11. I Genis A Fisher DM Michaelson 1999 Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment J Neurochem 72 206 213 10.1046/j.1471-4159.1999.0720206.x 9886071 (Pubitemid 29013894)
12. Z Gu P Zhong Z Yan 2003 Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices J Biol Chem 278 7546 7556
13. R Haring A Fisher D Marciano Z Pittel Y Kloog A Zuckerman N Eshhar E Heldman 1998 Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion J Neurochem 71 2094 2103 9798935
14. J Hyttel JB Nielsen G Nowak 1992 The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies) J Neural Transm Gen Sect 89 61 69 10.1007/BF01245352 1329856
15. Krosgaard-Larsen (1990) 4,5,6,7-Tetrahydroisothiazolo (4,5-c) pyridine derivatives. United States Patent 4,923,880
16. SYC Kumar MP Sadashiva KS Rangappa 2007 An efficient synthesis of 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)morpholine: a potent M1 selective muscarinic agonist Tetrahedron Lett 48 4565 4568 10.1016/j.tetlet.2007.04.135 (Pubitemid 46818375)
17. C Leloup DM Michaelson A Fisher T Hartmann K Beyreuther R Stein 2000 M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways Cell Death Differ 7 825 833 10.1038/sj.cdd.4400713 11042677
18. AI Levey 1996 Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease Proc Natl Acad Sci USA 93 13541 13546 10.1073/pnas.93.24.13541 8942969 (Pubitemid 26424154)
19. L Lin B Georgievska A Mattsson O Isacson 1999 Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation Proc Natl Acad Sci USA 96 12108 12113 10.1073/pnas.96.21.12108 10518584 (Pubitemid 29502866)
20. OH Lowry NJ Rosebrough AL Farr RJ Randall 1951 Protein measurement with the Folin phenol reagent J Biol Chem 193 265 275 14907713
21. XH Ma P Zhong Z Gu J Feng Z Yan 2003 Muscarinic potentiation of GABA(A) receptor currents is gated by insulin signaling in the prefrontal cortex J Neurosci 23 1159 1168 12598604
22. M Malviya YC Kumar D Asha JN Chandra MN Subhash KS Rangappa 2008 Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models Bioorg Med Chem 16 7095 7101 10.1016/j.bmc.2008.06.053 18640043
23. GA McPherson 1983 A practical computer-based approach to the analysis of radioligand binding experiments Comput Programs Biomed 17 107 113 10.1016/0010-468X(83)90031-4 6319079
24. A Nieoullon 2004 Alzheimer's disease: neurobiological advances supporting proposals for new therapeutical approaches J Appl Biomed 2 123 130
25. RM Nitsch BE Slack RJ Wurtman JH Growdon 1992 Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors Science 258 304 307 10.1126/science.1411529 1411529
26. AM Palmer 2002 Pharmacotherapy for Alzheimer's disease: progress and prospects Trends Pharmacol Sci 23 426 433 10.1016/S0165-6147(02)02056-4 12237155 (Pubitemid 35247772)
27. E Sadot D Gurwitz J Barg L Behar I Ginzburg A Fisher 1996 Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells J Neurochem 66 877 880 8592166
28. P Sauerberg JW Kindtler L Nielsen MJ Sheardown T Honore 1991 Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1, 2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships J Med Chem 34 687 692 10.1021/jm00106a033 1995893
29. P Sauerberg PH Olesen S Nielsen S Treppendahl MJ Sheardown T Honore CH Mitch JS Ward AJ Pike FP Bymaster 1992 Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5- thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines J Med Chem 35 2274 2283 10.1021/jm00090a019 1613751
30. DJ Selkoe 1994 Alzheimer's disease: a central role for amyloid J Neuropathol Exp Neurol 53 438 447 10.1097/00005072-199409000-00003 8083687
31. DJ Selkoe 2001 Alzheimer's disease: genes, proteins and therapy Physiol Rev 81 741 766 11274343
32. AC Sharma SK Kulkarni 1990 Evidence for GABA-BZ receptor modulation in short-term memory passive avoidance task paradigm in mice Methods Find Exp Clin Pharmacol 12 175 180 2161973
33. AC Sharma SK Kulkarni 1991 Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice Methods Find Exp Clin Pharmacol 13 155 159 1828849
34. R Wijtmans MKS Vink HEF Schoemaker L Van Delft RH Blaauw FPJT Rutjes 2004 Biological relevance and synthesis of C-substituted morpholine derivatives Synthesis 5 641 662
35. HI Yamamura SH Snyder 1974 Muscarinic cholinergic binding in rat brain Proc Natl Acad Sci USA 71 1725 1729 10.1073/pnas.71.5.1725 4151898